Marketing-authorisation holder · Canada
UCB Canada Inc
34 medicines in 1 country, as authorisation holder.
Loading your page…
Loading your page…
Marketing-authorisation holder · Canada
34 medicines in 1 country, as authorisation holder.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
1–25 of 34
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| BIMZELX320 mg / 2 ml · Solution | Bimekizumab | Canada | Marketed | 2025 |
| BIMZELX160 mg / ml · Solution | Bimekizumab | Canada | Marketed | 2022 |
| BIMZELX320 mg / 2 ml · Solution | Bimekizumab | Canada | Marketed | 2025 |
| BIMZELX160 mg / ml · Solution | Bimekizumab | Canada | Marketed | 2022 |
| BRIVLERA10 mg / ml · Solution | Brivaracetam | Canada | Marketed | 2018 |
| BRIVLERA50 mg · Tablet | Brivaracetam | Canada | Marketed | 2016 |
| BRIVLERA100 mg · Tablet | Brivaracetam | Canada | Marketed | 2016 |
| BRIVLERA10 mg · Tablet | Brivaracetam | Canada | Marketed | 2016 |
| BRIVLERA10 mg / ml · Solution | Brivaracetam | Canada | Marketed | 2020 |
| BRIVLERA75 mg · Tablet | Brivaracetam | Canada | Marketed | 2016 |
| BRIVLERA25 mg · Tablet | Brivaracetam | Canada | Marketed | 2016 |
| CIMZIA200 mg / ml · Solution | Certolizumab pegol | Canada | Marketed | 2009 |
| CIMZIA200 mg / ml · Solution | Certolizumab pegol | Canada | Marketed | 2017 |
| KEPPRA750 mg · Tablet | Levetiracetam | Canada | Marketed | 2003 |
| KEPPRA250 mg · Tablet | Levetiracetam | Canada | Marketed | 2003 |
| KEPPRA500 mg · Tablet | Levetiracetam | Canada | Marketed | 2003 |
| NEUPRO2 mg / 24 hour · Patch | Rotigotine | Canada | Marketed | 2013 |
| NEUPRO3 mg / 24 hour · Patch | Rotigotine | Canada | Marketed | 2013 |
| NEUPRO6 mg / 24 hour · Patch | Rotigotine | Canada | Marketed | 2013 |
| NEUPRO4 mg / 24 hour · Patch | Rotigotine | Canada | Marketed | 2013 |
| NEUPRO8 mg / 24 hour · Patch | Rotigotine | Canada | Marketed | 2013 |
| NEUPRO1 mg / 24 hour · Patch | Rotigotine | Canada | Marketed | 2013 |
| RYSTIGGO840 mg / 6 ml · Solution | Rozanolixizumab | Canada | Authorised | |
| RYSTIGGO280 mg / 2 ml · Solution | Rozanolixizumab | Canada | Marketed | 2025 |
| RYSTIGGO420 mg / 3 ml · Solution | Rozanolixizumab | Canada | Authorised |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| Canada | 34 | 34 | 0 | CompaniesAll medicines |
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Health Canada, Drug Product Database, company API, entire response observed 2026-10-10T15:12:05.508784+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Report an error or request removalCorrections from the company itself are welcome.
Other companies in the same group.
Ranked by their number of medicines.